...cGMP production via different routes. PL-3994 from Palatin Technologies Inc....
...to enter Phase II testing this quarter. Palatin...

...immunomodulators Fulcrum and Theravance also announced trial starts this week, with a third therapeutic from Palatin Technologies Inc....
...acute lung injury and cytokine storm initiation, preventing progression to acute respiratory distress syndrome (ARDS). Palatin...
...BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum Therapeutics Inc. Palatin Technologies Inc. [MERGED]...

...patisiran to treat hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Licensed from Palatin Technologies Inc....

...MC4R agonist will be available in September. The approval triggered a $60 million payment to Palatin Technologies Inc....
...VX-661)/ivacaftor, Tez/Iva Talzenna, talazoparib (MDV3800, bmn 673, bmn-673, lt-673) AMAG Pharmaceuticals Inc. Sio Gene Therapies Inc. Gilead Sciences Inc. Novartis AG Palatin Technologies Inc. Pfizer...

...nivolumab plus Yervoy ipilimumab Treat advanced non-small cell lung cancer (NSCLC) Phase III data 2Q19 Palatin Technologies Inc....

...First-line NSCLC in patients with tumor mutational burden ≥10 mutations per megabase PDUFA date 5/20/19 Palatin Technologies Inc....

...survived and had complete tumor regression, whereas all mice treated with C. novyi -NT died. Palatin Technologies Inc....
...U.S. to treat hypertension in patients with pheochromocytoma. Mary Romeo Demser, metyrosine (ONO-5371) PL-3994 Bausch Health Companies Inc. Johns Hopkins University Palatin Technologies Inc. Natriuretic...

...Pharmaceutical Inc. (NASDAQ:OHRP) Squalamine eye drops (OHR-102) Wet AMD Ph III MAKO data Early 2018 Palatin Technologies Inc....

...Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin...
...double-digit royalties. Palatin and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), which holds exclusive North American rights from Palatin...
...FDA in 1Q18 for the melanocortin 4 receptor (MC4R) agonist (see BioCentury, Jan. 20 ). Palatin Technologies Inc....